The company reported worldwide sales of $5.15 billion in the second quarter of 2008, an increase of 11% compared with the $4.63 billion posted in the corresponding period of 2007.
For the first half of 2008, the company reported total sales of $9.95 billion, an increase of 12%, compared with $8.85 billion in the prior-year period.
John Lechleiter, Lilly’s president and CEO, said: “Lilly continued to deliver solid financial results in the second quarter, including double-digit growth in sales and earnings. Our newer products, including Cymbalta, Cialis, and Alimta, continued to perform exceptionally well, while our diabetes care franchise has made good progress.
“During the quarter, we also remained engaged in business development activities designed to strengthen our R&D capabilities, resulting in both the in-licensing deal with TransPharma and the announced acquisition of SGX Pharmaceuticals.”